5-bromo-5'-phenyl-1,2',3,3'-tetrahydrospiro[2H-indole-3,2'-(1,3,4)-thiadiazole]-2-one manufacturers
- Lipofermata
-
- $54.00 / 1mg
-
2025-05-10
- CAS:297180-15-5
- Min. Order:
- Purity: 99.65%
- Supply Ability: 10g
- Lipofermata
-
- $54.00 / 1mg
-
2025-05-10
- CAS:297180-15-5
- Min. Order:
- Purity: 99.65%
- Supply Ability: 10g
|
| 5-bromo-5'-phenyl-1,2',3,3'-tetrahydrospiro[2H-indole-3,2'-(1,3,4)-thiadiazole]-2-one Basic information |
Product Name: | 5-bromo-5'-phenyl-1,2',3,3'-tetrahydrospiro[2H-indole-3,2'-(1,3,4)-thiadiazole]-2-one | Synonyms: | 5-bromo-5'-phenyl-1,2',3,3'-tetrahydrospiro[2H-indole-3,2'-(1,3,4)-thiadiazole]-2-one;5-bromo-5'-phenyl-3'H-spiro[indole-3,2'-[1,3,4]thiadiazol]-2(1H)-one;CB16.2 aka;Spiro[3H-indole-3,2'(3'H)-[1,3,4]thiadiazol]-2(1H)-one, 5-bromo-5'-phenyl-;5-bromo-5'-phenyl-3'H-spiro[indoline-3,2'-[1,3,4]thiadiazol]-2-one;5-Bromo-5’phenylspiro[1H-indole-3,2’-3H-1,3,4-thiadiazole]-2-one;5-bromo-5'-phenyl-spiro[3H-indole-3,2'(3'H)-[1,3,4]thiadiazol]-2(1H)-one;Lipofermata,Inhibitor,Bacterial,inhibit | CAS: | 297180-15-5 | MF: | C15H10BrN3OS | MW: | 360.23 | EINECS: | | Product Categories: | | Mol File: | 297180-15-5.mol | ![5-bromo-5'-phenyl-1,2',3,3'-tetrahydrospiro[2H-indole-3,2'-(1,3,4)-thiadiazole]-2-one Structure](CAS/20200119/GIF/297180-15-5.gif) |
| 5-bromo-5'-phenyl-1,2',3,3'-tetrahydrospiro[2H-indole-3,2'-(1,3,4)-thiadiazole]-2-one Chemical Properties |
density | 1.76±0.1 g/cm3(Predicted) | storage temp. | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | solubility | Soluble in DMSO (up to 20 mg/ml). | pka | 0.44±0.20(Predicted) | form | solid | color | Off-white | Stability: | Stable for 1 year from date of purchase? as supplied. Solutions in DMSO may be stored at -20° for up to 1 month. |
| 5-bromo-5'-phenyl-1,2',3,3'-tetrahydrospiro[2H-indole-3,2'-(1,3,4)-thiadiazole]-2-one Usage And Synthesis |
Description | Lipofermata (297180-15-5) is an inhibitor of fatty acid transport protein 2 (FATP2; IC50?= 4.84 μM).1?It does not inhibit glucose transport or the activity of long chain acyl-CoA synthetase. It prevented palmitate-mediated oxidative stress, induction of BiP and CHOP, and cell death in a dose-dependent manner in hsHepG2 and mINS-1E cells suggesting utility in preventing fatty acid-mediated cell death pathways and lipotoxic disease.2?Inhibition was specific for long and very long chain fatty acids but not medium (C6-C10) acids. Lipofermata abrogates lipid transport into melanoma cells and reduces melanoma growth and invasion.3 | Uses | Lipofermata is a fatty acid transport proteins (FATPs) inhibitor. | References | 1) Sandoval?et al.?(2010),?Identification and characterization of small compound inhibitors of human FATP2; Biochem. Pharmacol.?79?990
2) Ahowesso?et al.?(2015),?Chemical inhibition of fatty acid absorption and cellular uptake limits lipotoxic cell death; Biochem. Pharmacol.?98?167
3) Zhang?et al.?(2018),?Adipocyte-derived lipids mediate melanoma progression via FATP proteins; Cancer Discov.?8?1006
br /> |
| 5-bromo-5'-phenyl-1,2',3,3'-tetrahydrospiro[2H-indole-3,2'-(1,3,4)-thiadiazole]-2-one Preparation Products And Raw materials |
|